Towards enzyme activated antiprostatic agents.
A prodrug conjugate designed to undergo activation by enzymatic prostate specific antigen has been synthesized. The prodrug system undergoes activation with PSA or alpha-chymotrypsin, and shows selective cytotoxicity in a PSA secreting cell line.